Talis Biomedical Corporation announced the appointment of Jeryl “Jeri” Hilleman to its Board of Directors. Ms. Hilleman will serve as Chair of the Audit Committee. Ms. Hilleman brings over 20 years of executive leadership and financial experience to Talis. She currently serves as Chairman of the Board of Omada Health and is a Director of Novocure, SI-Bone and Minerva Neurosciences. Prior to her decision to focus on board responsibilities full time in 2020, Ms. Hilleman served as a Chief Financial Officer for more than 20 years at multiple public companies in the life science industry, including Intersect ENT, Ocera Therapeutics, Amyris, Symyx Technologies and Cytel.